{"transactions":[{"id":676236,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":19945,"kind":"person","name":"Hill Stephen J.","position":1,"cik":"0001866154","reported_name":"Hill Stephen J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2026-08-25T20:05:18.000Z","date":"2026-08-21","kind":"sale","planned":false,"acquired":false,"shares":989,"price":15.54,"value":15369.06,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units."}],"balance_after":16816,"source":{"system":"sec-edgar","filing":"0001866154-26-000006","document":"form4-08252026_080813.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1866154/000186615426000006/form4-08252026_080813.xml","form_type":"4"}},{"id":690893,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":19945,"kind":"person","name":"Hill Stephen J.","position":1,"cik":"0001866154","reported_name":"Hill Stephen J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2026-08-11T20:18:15.000Z","date":"2026-08-10","kind":"sale","planned":false,"acquired":false,"shares":89,"price":14.34,"value":1276.26,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported above reflects the weighted average price of the shares sold. The sale price ranged from $14.27 to $14.34 per share. Upon request from the SEC staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4."}],"balance_after":17805,"source":{"system":"sec-edgar","filing":"0001866154-26-000004","document":"form4-08112026_080811.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1866154/000186615426000004/form4-08112026_080811.xml","form_type":"4"}},{"id":737963,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":19945,"kind":"person","name":"Hill Stephen J.","position":1,"cik":"0001866154","reported_name":"Hill Stephen J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2026-06-15T22:34:03.000Z","date":"2026-05-11","kind":"sale","planned":false,"acquired":false,"shares":89,"price":18.92,"value":1683.88,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported above reflects the weighted average price of the shares sold. The sale price ranged from $18.91 to $19.30 per share. Upon request from the SEC staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 188 shares acquired on May 18, 2026 under the Issuer's 2021 Employee Stock Purchase Plan."}],"balance_after":17894,"source":{"system":"sec-edgar","filing":"0001866154-26-000003","document":"form4-06152026_100659.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1866154/000186615426000003/form4-06152026_100659.xml","form_type":"4"}},{"id":907749,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":19945,"kind":"person","name":"Hill Stephen J.","position":1,"cik":"0001866154","reported_name":"Hill Stephen J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2026-02-13T01:46:32.000Z","date":"2026-02-11","kind":"sale","planned":false,"acquired":false,"shares":1236,"price":23.39,"value":28910.04,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares automatically sold to cover tax withholding obligation from settlement of performance-based vested restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported above reflects the weighted average price of the shares sold. The sale price ranged from $23.3939 to $24.7850 per share. Upon request from the SEC staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4."}],"balance_after":17795,"source":{"system":"sec-edgar","filing":"0001866154-26-000002","document":"form4-02132026_010228.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1866154/000186615426000002/form4-02132026_010228.xml","form_type":"4"}},{"id":910136,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":19945,"kind":"person","name":"Hill Stephen J.","position":1,"cik":"0001866154","reported_name":"Hill Stephen J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Option (right to buy)","published_at":"2026-02-12T02:05:21.000Z","date":"2026-02-10","kind":"grant","planned":false,"acquired":true,"shares":65000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Twelve and one-half percent (12.5%) of the total number of shares of Common Stock subject to the option will be vested and exercisable on the date that is six (6) months after February 9, 2026 (the \"Vesting Commencement Date\") and thereafter, an additional one fortyeighth\n(1/48th) of the shares will become vested and exercisable monthly on the same day as the Vesting Commencement Date (or, if there is no such corresponding day for a given month, on the last day of such month), until the option has become vested and exercisable\nwith respect to one hundred percent (100%) of the shares, subject to the Reporting Person providing service to the Issuer through each applicable vesting date."}],"balance_after":65000,"derivative":{"exercise_price":23.71,"expiration_date":"2036-02-09","underlying":"Common Stock","underlying_shares":65000},"source":{"system":"sec-edgar","filing":"0001866154-26-000001","document":"form4-02122026_020218.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1866154/000186615426000001/form4-02122026_020218.xml","form_type":"4"}},{"id":910135,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":19945,"kind":"person","name":"Hill Stephen J.","position":1,"cik":"0001866154","reported_name":"Hill Stephen J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2026-02-12T02:05:21.000Z","date":"2026-02-10","kind":"sale","planned":false,"acquired":false,"shares":109,"price":23.12,"value":2520.08,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units."}],"balance_after":19031,"source":{"system":"sec-edgar","filing":"0001866154-26-000001","document":"form4-02122026_020218.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1866154/000186615426000001/form4-02122026_020218.xml","form_type":"4"}},{"id":910134,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":19945,"kind":"person","name":"Hill Stephen J.","position":1,"cik":"0001866154","reported_name":"Hill Stephen J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2026-02-12T02:05:21.000Z","date":"2026-02-09","kind":"grant","planned":false,"acquired":true,"shares":4000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Pursuant to performance-based restricted stock units granted to the reporting person on February 9, 2024, 4,000 shares were issued on the Transaction Date upon the achievement of certain performance criteria certified by the compensation committee of the Issuer's\nboard of directors on the Transaction Date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 390 shares acquired on November 18, 2025 under the Issuer's 2021 Employee Stock Purchase Plan."}],"balance_after":19140,"source":{"system":"sec-edgar","filing":"0001866154-26-000001","document":"form4-02122026_020218.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1866154/000186615426000001/form4-02122026_020218.xml","form_type":"4"}},{"id":1002144,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":19945,"kind":"person","name":"Hill Stephen J.","position":1,"cik":"0001866154","reported_name":"Hill Stephen J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2025-11-13T01:31:56.000Z","date":"2025-11-10","kind":"sale","planned":false,"acquired":false,"shares":95,"price":16.12,"value":1531.4,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units."}],"balance_after":15750,"source":{"system":"sec-edgar","filing":"0001866154-25-000006","document":"form4-11132025_011153.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1866154/000186615425000006/form4-11132025_011153.xml","form_type":"4"}},{"id":1012105,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":19945,"kind":"person","name":"Hill Stephen J.","position":1,"cik":"0001866154","reported_name":"Hill Stephen J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Option (right to buy)","published_at":"2025-10-29T21:42:53.000Z","date":"2025-10-27","kind":"grant","planned":false,"acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"12.5% of the option shares will vest on April 27, 2026, with the remaining option shares to vest in equal monthly installments over the following forty-two months, subject to the reporting person providing service through the applicable vesting date."}],"balance_after":75000,"derivative":{"exercise_price":17.23,"expiration_date":"2035-10-26","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001866154-25-000005","document":"form4-10292025_091048.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1866154/000186615425000005/form4-10292025_091048.xml","form_type":"4"}},{"id":1058350,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":19945,"kind":"person","name":"Hill Stephen J.","position":1,"cik":"0001866154","reported_name":"Hill Stephen J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2025-08-22T20:06:04.000Z","date":"2025-08-21","kind":"sale","planned":false,"acquired":false,"shares":1004,"price":10.544,"value":10586.176,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported above reflects the weighted average price of the shares sold. The sale price ranged from $10.49 to $10.64 per share. Upon request from the SEC staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4."}],"balance_after":15845,"source":{"system":"sec-edgar","filing":"0001415889-25-022746","document":"form4-08222025_080857.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1866154/000141588925022746/form4-08222025_080857.xml","form_type":"4"}},{"id":1058349,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":19945,"kind":"person","name":"Hill Stephen J.","position":1,"cik":"0001866154","reported_name":"Hill Stephen J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2025-08-22T20:06:04.000Z","date":"2025-08-20","kind":"grant","planned":false,"acquired":true,"shares":8000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Pursuant to performance-based restricted stock units granted to the reporting person on February 9, 2024, 4,000 shares were issued on the Transaction Date upon the achievement of certain performance criteria certified by the compensation committee of the Issuer's board of directors on the Transaction Date and 4,000 shares will be issued on August 20, 2026, subject to the reporting person providing service through such date."}],"balance_after":16849,"source":{"system":"sec-edgar","filing":"0001415889-25-022746","document":"form4-08222025_080857.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1866154/000141588925022746/form4-08222025_080857.xml","form_type":"4"}},{"id":1067907,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":19945,"kind":"person","name":"Hill Stephen J.","position":1,"cik":"0001866154","reported_name":"Hill Stephen J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2025-08-14T01:09:33.000Z","date":"2025-08-12","kind":"sale","planned":false,"acquired":false,"shares":94,"price":10.338,"value":971.772,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F5","text":"Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported above reflects the weighted average price of the shares sold. The sale price ranged from $10.120 to $10.415 per share. Upon request from the SEC staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F7","text":"On May 30, 2025, the Issuer effected a 1-for-20 reverse stock split of its common stock. All share and amounts reported herein reflect the reverse stock split."}],"balance_after":8849,"source":{"system":"sec-edgar","filing":"0001415889-25-021693","document":"form4-08142025_010830.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1866154/000141588925021693/form4-08142025_010830.xml","form_type":"4"}},{"id":1067906,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":19945,"kind":"person","name":"Hill Stephen J.","position":1,"cik":"0001866154","reported_name":"Hill Stephen J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2025-08-14T01:09:33.000Z","date":"2025-08-11","kind":"sale","planned":false,"acquired":false,"shares":91,"price":10.526,"value":957.866,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported above reflects the weighted average price of the shares sold. The sale price ranged from $10.045 to $11.00 per share. Upon request from the SEC staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 390 shares acquired on May 18, 2025 under the Issuer's 2021 Employee Stock Purchase Plan."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"On May 30, 2025, the Issuer effected a 1-for-20 reverse stock split of its common stock. All share and amounts reported herein reflect the reverse stock split."}],"balance_after":8943,"source":{"system":"sec-edgar","filing":"0001415889-25-021693","document":"form4-08142025_010830.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1866154/000141588925021693/form4-08142025_010830.xml","form_type":"4"}},{"id":1243488,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":19945,"kind":"person","name":"Hill Stephen J.","position":1,"cik":"0001866154","reported_name":"Hill Stephen J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Option (right to buy)","published_at":"2025-02-27T00:31:23.000Z","date":"2025-02-10","kind":"grant","planned":false,"acquired":true,"shares":56250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The reported transaction involved the reporting person's receipt of a grant of performance-based options, subject to vesting upon the achievement of specified performance criteria."}],"balance_after":56250,"derivative":{"exercise_price":0.5535,"expiration_date":"2035-02-09","underlying":"Common Stock","underlying_shares":56250},"source":{"system":"sec-edgar","filing":"0001415889-25-005760","document":"form4-02272025_120219.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1866154/000141588925005760/form4-02272025_120219.xml","form_type":"4"}},{"id":1243487,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":19945,"kind":"person","name":"Hill Stephen J.","position":1,"cik":"0001866154","reported_name":"Hill Stephen J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Option (right to buy)","published_at":"2025-02-27T00:31:23.000Z","date":"2025-02-10","kind":"grant","planned":false,"acquired":true,"shares":450000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"12.5% of the option shares will vest on August 9, 2025, with the remaining option shares to vest in equal monthly installments over the following forty-two months, subject to the reporting person providing service through the applicable vesting date."}],"balance_after":450000,"derivative":{"exercise_price":0.5535,"expiration_date":"2035-02-09","underlying":"Common Stock","underlying_shares":450000},"source":{"system":"sec-edgar","filing":"0001415889-25-005760","document":"form4-02272025_120219.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1866154/000141588925005760/form4-02272025_120219.xml","form_type":"4"}},{"id":1243486,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":19945,"kind":"person","name":"Hill Stephen J.","position":1,"cik":"0001866154","reported_name":"Hill Stephen J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2025-02-27T00:31:23.000Z","date":"2025-02-10","kind":"grant","planned":false,"acquired":true,"shares":112500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"12.5% of the total number of restricted stock units will vest on August 9, 2025, and thereafter an additional 1/16th of the total number of restricted stock units will vest quarterly thereafter, subject to the reporting person providing service through the applicable vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 7,707 shares acquired on May 17, 2024 and 3,764 shares acquired on  November 18, 2024 under the Issuer's 2021 Employee Stock Purchase Plan."}],"balance_after":172899,"source":{"system":"sec-edgar","filing":"0001415889-25-005760","document":"form4-02272025_120219.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1866154/000141588925005760/form4-02272025_120219.xml","form_type":"4"}},{"id":1646535,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":19945,"kind":"person","name":"Hill Stephen J.","position":1,"cik":"0001866154","reported_name":"Hill Stephen J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-02-14T01:24:01.000Z","date":"2024-02-09","kind":"grant","planned":false,"acquired":true,"shares":400000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"12.5% of the option shares shall vest on August 9, 2024, with the remaining option shares to vest in equal monthly installments over the following forty-two months."}],"balance_after":400000,"derivative":{"exercise_price":1.8,"expiration_date":"2034-02-08","underlying":"Common Stock","underlying_shares":400000},"source":{"system":"sec-edgar","filing":"0001209191-24-003274","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1866154/000120919124003274/doc4.xml","form_type":"4"}},{"id":1646534,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":19945,"kind":"person","name":"Hill Stephen J.","position":1,"cik":"0001866154","reported_name":"Hill Stephen J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2024-02-14T01:24:01.000Z","date":"2024-02-09","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"The reported transaction involved the Reporting Person's receipt of a grant of performance-based restricted stock units, subject to vesting upon the achievement of specified performance criteria. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 2,941 shares acquired on May 18, 2022, 5,434 shares acquired on May 18, 2023 and 553 shares acquired on November 17, 2023 under the Issuer's 2021 Employee Stock Purchase Plan."}],"balance_after":48928,"source":{"system":"sec-edgar","filing":"0001209191-24-003274","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1866154/000120919124003274/doc4.xml","form_type":"4"}},{"id":1734852,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":19945,"kind":"person","name":"Hill Stephen J.","position":1,"cik":"0001866154","reported_name":"Hill Stephen J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technical Ops. Officer"}}],"security":"Stock Option (right to buy)","published_at":"2023-11-21T01:52:09.000Z","date":"2023-11-16","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":700000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transactions reported herein reflect a one-time stock option repricing (the \"Option Repricing\") effective on November 16, 2023 (the \"Repricing Date\"). The Option Repricing applies to options with exercise prices greater than $2.37 per share held by all continuing employees of the Issuer as of the Repricing Date."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Option Repricing, the exercise price of the repriced options, including the Option, has been amended to reduce the exercise price to $1.87 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. In addition, the vesting schedule for the unvested shares underlying repriced options held by executive officers, including the reporting person, was extended for an additional year. There is no change to the expiration dates of or number of shares underlying the repriced options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F14","text":"12.5% of the option shares vested on August 9, 2022, with the remaining option shares to vest in equal monthly installments over the following\nforty-two months."}],"balance_after":0,"derivative":{"exercise_price":5.98,"expiration_date":"2032-03-15","underlying":"Common Stock","underlying_shares":700000},"source":{"system":"sec-edgar","filing":"0001209191-23-056178","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1866154/000120919123056178/doc4.xml","form_type":"4"}},{"id":1734851,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":19945,"kind":"person","name":"Hill Stephen J.","position":1,"cik":"0001866154","reported_name":"Hill Stephen J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technical Ops. Officer"}}],"security":"Stock Option (right to buy)","published_at":"2023-11-21T01:52:09.000Z","date":"2023-11-16","kind":"grant","planned":false,"acquired":true,"shares":700000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transactions reported herein reflect a one-time stock option repricing (the \"Option Repricing\") effective on November 16, 2023 (the \"Repricing Date\"). The Option Repricing applies to options with exercise prices greater than $2.37 per share held by all continuing employees of the Issuer as of the Repricing Date."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Option Repricing, the exercise price of the repriced options, including the Option, has been amended to reduce the exercise price to $1.87 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. In addition, the vesting schedule for the unvested shares underlying repriced options held by executive officers, including the reporting person, was extended for an additional year. There is no change to the expiration dates of or number of shares underlying the repriced options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F13","text":"306,250 shares were vested as of November 16, 2023 and the remaining unvested shares will vest in equal monthly installments over the following thirty-nine months based on the original vesting commencement date."}],"balance_after":700000,"derivative":{"exercise_price":1.87,"expiration_date":"2032-03-15","underlying":"Common Stock","underlying_shares":700000},"source":{"system":"sec-edgar","filing":"0001209191-23-056178","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1866154/000120919123056178/doc4.xml","form_type":"4"}},{"id":1734850,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":19945,"kind":"person","name":"Hill Stephen J.","position":1,"cik":"0001866154","reported_name":"Hill Stephen J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technical Ops. Officer"}}],"security":"Stock Option (right to buy)","published_at":"2023-11-21T01:52:09.000Z","date":"2023-11-16","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":85000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transactions reported herein reflect a one-time stock option repricing (the \"Option Repricing\") effective on November 16, 2023 (the \"Repricing Date\"). The Option Repricing applies to options with exercise prices greater than $2.37 per share held by all continuing employees of the Issuer as of the Repricing Date."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Option Repricing, the exercise price of the repriced options, including the Option, has been amended to reduce the exercise price to $1.87 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. In addition, the vesting schedule for the unvested shares underlying repriced options held by executive officers, including the reporting person, was extended for an additional year. There is no change to the expiration dates of or number of shares underlying the repriced options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F12","text":"1/48th of the total shares vest in equal monthly installments over the forty-eight months following April 14, 2021."}],"balance_after":0,"derivative":{"exercise_price":12.67,"expiration_date":"2031-04-13","underlying":"Common Stock","underlying_shares":85000},"source":{"system":"sec-edgar","filing":"0001209191-23-056178","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1866154/000120919123056178/doc4.xml","form_type":"4"}},{"id":1734849,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":19945,"kind":"person","name":"Hill Stephen J.","position":1,"cik":"0001866154","reported_name":"Hill Stephen J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technical Ops. Officer"}}],"security":"Stock Option (right to buy)","published_at":"2023-11-21T01:52:09.000Z","date":"2023-11-16","kind":"grant","planned":false,"acquired":true,"shares":85000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transactions reported herein reflect a one-time stock option repricing (the \"Option Repricing\") effective on November 16, 2023 (the \"Repricing Date\"). The Option Repricing applies to options with exercise prices greater than $2.37 per share held by all continuing employees of the Issuer as of the Repricing Date."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Option Repricing, the exercise price of the repriced options, including the Option, has been amended to reduce the exercise price to $1.87 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. In addition, the vesting schedule for the unvested shares underlying repriced options held by executive officers, including the reporting person, was extended for an additional year. There is no change to the expiration dates of or number of shares underlying the repriced options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F11","text":"54,896 shares were vested as of November 16, 2023 and the remaining unvested shares will vest in equal monthly installments over the following twenty-nine months based on the original vesting commencement date."}],"balance_after":85000,"derivative":{"exercise_price":1.87,"expiration_date":"2031-04-13","underlying":"Common Stock","underlying_shares":85000},"source":{"system":"sec-edgar","filing":"0001209191-23-056178","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1866154/000120919123056178/doc4.xml","form_type":"4"}},{"id":1734848,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":19945,"kind":"person","name":"Hill Stephen J.","position":1,"cik":"0001866154","reported_name":"Hill Stephen J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technical Ops. Officer"}}],"security":"Stock Option (right to buy)","published_at":"2023-11-21T01:52:09.000Z","date":"2023-11-16","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":100000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transactions reported herein reflect a one-time stock option repricing (the \"Option Repricing\") effective on November 16, 2023 (the \"Repricing Date\"). The Option Repricing applies to options with exercise prices greater than $2.37 per share held by all continuing employees of the Issuer as of the Repricing Date."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Option Repricing, the exercise price of the repriced options, including the Option, has been amended to reduce the exercise price to $1.87 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. In addition, the vesting schedule for the unvested shares underlying repriced options held by executive officers, including the reporting person, was extended for an additional year. There is no change to the expiration dates of or number of shares underlying the repriced options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"1/48th of the total shares vest in equal monthly installments over the forty-eight months following March 1, 2021."}],"balance_after":0,"derivative":{"exercise_price":6.24,"expiration_date":"2031-02-11","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001209191-23-056178","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1866154/000120919123056178/doc4.xml","form_type":"4"}},{"id":1734847,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":19945,"kind":"person","name":"Hill Stephen J.","position":1,"cik":"0001866154","reported_name":"Hill Stephen J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technical Ops. Officer"}}],"security":"Stock Option (right to buy)","published_at":"2023-11-21T01:52:09.000Z","date":"2023-11-16","kind":"grant","planned":false,"acquired":true,"shares":100000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transactions reported herein reflect a one-time stock option repricing (the \"Option Repricing\") effective on November 16, 2023 (the \"Repricing Date\"). The Option Repricing applies to options with exercise prices greater than $2.37 per share held by all continuing employees of the Issuer as of the Repricing Date."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Option Repricing, the exercise price of the repriced options, including the Option, has been amended to reduce the exercise price to $1.87 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. In addition, the vesting schedule for the unvested shares underlying repriced options held by executive officers, including the reporting person, was extended for an additional year. There is no change to the expiration dates of or number of shares underlying the repriced options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"66,667 shares were vested as of November 16, 2023 and the remaining unvested shares will vest in equal monthly installments over the following twenty-eight months based on the original vesting commencement date."}],"balance_after":100000,"derivative":{"exercise_price":1.87,"expiration_date":"2031-02-11","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001209191-23-056178","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1866154/000120919123056178/doc4.xml","form_type":"4"}},{"id":1734846,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":19945,"kind":"person","name":"Hill Stephen J.","position":1,"cik":"0001866154","reported_name":"Hill Stephen J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technical Ops. Officer"}}],"security":"Stock Option (right to buy)","published_at":"2023-11-21T01:52:09.000Z","date":"2023-11-16","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":450000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transactions reported herein reflect a one-time stock option repricing (the \"Option Repricing\") effective on November 16, 2023 (the \"Repricing Date\"). The Option Repricing applies to options with exercise prices greater than $2.37 per share held by all continuing employees of the Issuer as of the Repricing Date."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Option Repricing, the exercise price of the repriced options, including the Option, has been amended to reduce the exercise price to $1.87 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. In addition, the vesting schedule for the unvested shares underlying repriced options held by executive officers, including the reporting person, was extended for an additional year. There is no change to the expiration dates of or number of shares underlying the repriced options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"1/48th of the total shares vest in equal monthly installments over the forty-eight months following December 1, 2020."}],"balance_after":0,"derivative":{"exercise_price":5.96,"expiration_date":"2030-11-16","underlying":"Common Stock","underlying_shares":450000},"source":{"system":"sec-edgar","filing":"0001209191-23-056178","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1866154/000120919123056178/doc4.xml","form_type":"4"}},{"id":1734845,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":19945,"kind":"person","name":"Hill Stephen J.","position":1,"cik":"0001866154","reported_name":"Hill Stephen J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technical Ops. Officer"}}],"security":"Stock Option (right to buy)","published_at":"2023-11-21T01:52:09.000Z","date":"2023-11-16","kind":"grant","planned":false,"acquired":true,"shares":450000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transactions reported herein reflect a one-time stock option repricing (the \"Option Repricing\") effective on November 16, 2023 (the \"Repricing Date\"). The Option Repricing applies to options with exercise prices greater than $2.37 per share held by all continuing employees of the Issuer as of the Repricing Date."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Option Repricing, the exercise price of the repriced options, including the Option, has been amended to reduce the exercise price to $1.87 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. In addition, the vesting schedule for the unvested shares underlying repriced options held by executive officers, including the reporting person, was extended for an additional year. There is no change to the expiration dates of or number of shares underlying the repriced options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"328,125 shares were vested as of November 16, 2023 and the remaining unvested shares will vest in equal monthly installments over the following twenty-five months based on the original vesting commencement date."}],"balance_after":450000,"derivative":{"exercise_price":1.87,"expiration_date":"2030-11-16","underlying":"Common Stock","underlying_shares":450000},"source":{"system":"sec-edgar","filing":"0001209191-23-056178","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1866154/000120919123056178/doc4.xml","form_type":"4"}},{"id":1734844,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":19945,"kind":"person","name":"Hill Stephen J.","position":1,"cik":"0001866154","reported_name":"Hill Stephen J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technical Ops. Officer"}}],"security":"Stock Option (right to buy)","published_at":"2023-11-21T01:52:09.000Z","date":"2023-11-16","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":165000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transactions reported herein reflect a one-time stock option repricing (the \"Option Repricing\") effective on November 16, 2023 (the \"Repricing Date\"). The Option Repricing applies to options with exercise prices greater than $2.37 per share held by all continuing employees of the Issuer as of the Repricing Date."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Option Repricing, the exercise price of the repriced options, including the Option, has been amended to reduce the exercise price to $1.87 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. In addition, the vesting schedule for the unvested shares underlying repriced options held by executive officers, including the reporting person, was extended for an additional year. There is no change to the expiration dates of or number of shares underlying the repriced options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"1/48th of the total shares vest in equal monthly installments over the forty-eight months following February 1, 2020."}],"balance_after":0,"derivative":{"exercise_price":3.65,"expiration_date":"2030-01-15","underlying":"Common Stock","underlying_shares":165000},"source":{"system":"sec-edgar","filing":"0001209191-23-056178","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1866154/000120919123056178/doc4.xml","form_type":"4"}},{"id":1734843,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":19945,"kind":"person","name":"Hill Stephen J.","position":1,"cik":"0001866154","reported_name":"Hill Stephen J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technical Ops. Officer"}}],"security":"Stock Option (right to buy)","published_at":"2023-11-21T01:52:09.000Z","date":"2023-11-16","kind":"grant","planned":false,"acquired":true,"shares":165000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transactions reported herein reflect a one-time stock option repricing (the \"Option Repricing\") effective on November 16, 2023 (the \"Repricing Date\"). The Option Repricing applies to options with exercise prices greater than $2.37 per share held by all continuing employees of the Issuer as of the Repricing Date."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Option Repricing, the exercise price of the repriced options, including the Option, has been amended to reduce the exercise price to $1.87 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. In addition, the vesting schedule for the unvested shares underlying repriced options held by executive officers, including the reporting person, was extended for an additional year. There is no change to the expiration dates of or number of shares underlying the repriced options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"154,688 shares were vested as of November 16, 2023 and the remaining unvested shares will vest in equal monthly installments over the following fifteen months based on the original vesting commencement date."}],"balance_after":165000,"derivative":{"exercise_price":1.87,"expiration_date":"2030-01-15","underlying":"Common Stock","underlying_shares":165000},"source":{"system":"sec-edgar","filing":"0001209191-23-056178","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1866154/000120919123056178/doc4.xml","form_type":"4"}},{"id":1734842,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":19945,"kind":"person","name":"Hill Stephen J.","position":1,"cik":"0001866154","reported_name":"Hill Stephen J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technical Ops. Officer"}}],"security":"Stock Option (right to buy)","published_at":"2023-11-21T01:52:09.000Z","date":"2023-11-16","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":500000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transactions reported herein reflect a one-time stock option repricing (the \"Option Repricing\") effective on November 16, 2023 (the \"Repricing Date\"). The Option Repricing applies to options with exercise prices greater than $2.37 per share held by all continuing employees of the Issuer as of the Repricing Date."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Option Repricing, the exercise price of the repriced options, including the Option, has been amended to reduce the exercise price to $1.87 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. In addition, the vesting schedule for the unvested shares underlying repriced options held by executive officers, including the reporting person, was extended for an additional year. There is no change to the expiration dates of or number of shares underlying the repriced options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Fully-vested."}],"balance_after":0,"derivative":{"exercise_price":3.65,"expiration_date":"2029-11-30","underlying":"Common Stock","underlying_shares":500000},"source":{"system":"sec-edgar","filing":"0001209191-23-056178","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1866154/000120919123056178/doc4.xml","form_type":"4"}},{"id":1734841,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":19945,"kind":"person","name":"Hill Stephen J.","position":1,"cik":"0001866154","reported_name":"Hill Stephen J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technical Ops. Officer"}}],"security":"Stock Option (right to buy)","published_at":"2023-11-21T01:52:09.000Z","date":"2023-11-16","kind":"grant","planned":false,"acquired":true,"shares":500000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transactions reported herein reflect a one-time stock option repricing (the \"Option Repricing\") effective on November 16, 2023 (the \"Repricing Date\"). The Option Repricing applies to options with exercise prices greater than $2.37 per share held by all continuing employees of the Issuer as of the Repricing Date."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Option Repricing, the exercise price of the repriced options, including the Option, has been amended to reduce the exercise price to $1.87 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. In addition, the vesting schedule for the unvested shares underlying repriced options held by executive officers, including the reporting person, was extended for an additional year. There is no change to the expiration dates of or number of shares underlying the repriced options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Fully-vested."}],"balance_after":500000,"derivative":{"exercise_price":1.87,"expiration_date":"2029-11-30","underlying":"Common Stock","underlying_shares":500000},"source":{"system":"sec-edgar","filing":"0001209191-23-056178","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1866154/000120919123056178/doc4.xml","form_type":"4"}},{"id":1987468,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":19945,"kind":"person","name":"Hill Stephen J.","position":1,"cik":"0001866154","reported_name":"Hill Stephen J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technical Ops. Officer"}}],"security":"Option (right to buy)","published_at":"2023-02-28T23:21:00.000Z","date":"2023-02-24","kind":"grant","acquired":true,"shares":900000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"12.5% of the option shares shall vest on August 9, 2023, with the remaining option shares to vest in equal monthly installments over the following forty-two months."}],"balance_after":900000,"derivative":{"exercise_price":2.13,"expiration_date":"2033-02-23","underlying":"Common Stock","underlying_shares":900000},"source":{"system":"sec-edgar","filing":"0001209191-23-013850","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1866154/000120919123013850/doc4.xml","form_type":"4"}},{"id":2324977,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":19945,"kind":"person","name":"Hill Stephen J.","position":1,"cik":"0001866154","reported_name":"Hill Stephen J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technical Ops. Officer"}}],"security":"Option (right to buy)","published_at":"2022-03-18T20:05:36.000Z","date":"2022-03-16","kind":"grant","acquired":true,"shares":700000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"12.5% of the option shares shall vest on August 9, 2022, with the remaining option shares to vest in equal monthly installments over the following forty-two months."}],"balance_after":700000,"derivative":{"exercise_price":5.98,"expiration_date":"2032-03-15","underlying":"Common Stock","underlying_shares":700000},"source":{"system":"sec-edgar","filing":"0001209191-22-020001","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1866154/000120919122020001/doc4.xml","form_type":"4"}}]}